Image thumbnail

News Feature on ImmunoSEBᵀᴹ & ProbioSEB CSC3ᵀᴹ Research

News Feature on ImmunoSEBᵀᴹ & ProbioSEB CSC3ᵀᴹ Research

In an interview with Fox 26 Houston, Dr. Neha Shah discusses the promising results of a clinical trial on ImmunoSEBTM and ProbioSEB CSC3TM for people with COVID-19. Watch the full interview, and read the article here. 

The researchers used a combination of ImmunoSEBTM, a powerful systemic enzyme complex, and ProbioSEB CSC3TM, a spore-forming probiotic blend, including SEBioticTM (Bacillus coagulans LBSC), SEBtilisTM (Bacillus subtilis) and SEBclausiiTM (Bacillus clausii).

Dr. Shah and researchers said ImmunoSEBTM and ProbioSEB CSC3TM were effective, saying, “Ninety-three percent of patients who were receiving the supplements showed clinical improvement on day 10, versus only 60 percent of patients in the control group. We also saw that the clinical improvement was earlier in patients on the supplements. They were fever-free faster than patients in the controls, which did not receive the supplements, and also had reduced hospitalization time.”

You can learn more about the clinical trials done on ImmunoSEBTM and ProbioSEB CSC3TM, as well as other studies in our Science & Research section. To get in touch with someone from our support team, call us at (909) 613-1660, or contact us.